EPS for American Electric Power Company, Inc. (AEP) Expected At $0.81; Summit Therapeutics plc (SMMT) Covered By 4 Bullish Analysts Last Week

Summit Therapeutics plc (NASDAQ:SMMT) Logo

Analysts expect American Electric Power Company, Inc. (NYSE:AEP) to report $0.81 EPS on July, 26.They anticipate $0.06 EPS change or 8.00% from last quarter’s $0.75 EPS. AEP’s profit would be $398.94 million giving it 21.21 P/E if the $0.81 EPS is correct. After having $0.96 EPS previously, American Electric Power Company, Inc.’s analysts see -15.63% EPS growth. The stock decreased 0.89% or $0.62 during the last trading session, reaching $68.72. About 692,510 shares traded. American Electric Power Company, Inc. (NYSE:AEP) has declined 5.06% since June 29, 2017 and is downtrending. It has underperformed by 17.63% the S&P500. Some Historical AEP News: 26/04/2018 – American Electric Power 1Q Net $454.4M; 26/04/2018 – American Electric Power Sees FY Adj EPS $3.75-Adj EPS $3.95; 19/04/2018 – AMERICAN ELECTRIC POWER COMPANY INC – AEP FILED UPDATED TRANSMISSION FORMULA RATES THAT INCORPORATE BENEFITS OF TAX REFORM FOR TRANSMISSION CUSTOMERS; 26/03/2018 – AEP Recognized As A 2020 Women On Boards Winning Company; 02/04/2018 – AMERICAN ELECTRIC POWER COMPANY – PROPOSAL PACKAGES MUST BE RECEIVED BY AEP NO LATER THAN 5 P.M. APRIL 9, 2018; 30/05/2018 – GRIDLIANCE & TRI-COUNTY ELECTRIC REACH PACT WITH AEP; 26/04/2018 – American Electric Power 1Q EPS 92c; 30/05/2018 – GRIDLIANCE SAYS SETTLEMENT AGREEMENT WITH AMERICAN ELECTRIC POWER COMPANY RELATES TO PROPOSED WIND CATCHER ENERGY CONNECTION PROJECT; 17/04/2018 – FTC: 20181063: Grupo Comercial Chedraui, S.A.B. de C.V.; AEP III Fiesta AIV, L.P; 30/05/2018 – Texas power demand breaks May daily record during heat wave -ERCOT

Among 7 analysts covering Summit Therapeutics (NASDAQ:SMMT), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Summit Therapeutics had 12 analyst reports since January 4, 2018 according to SRatingsIntel. Janney Capital downgraded Summit Therapeutics plc (NASDAQ:SMMT) rating on Thursday, June 28. Janney Capital has “Neutral” rating and $3 target. The firm has “Buy” rating given on Tuesday, March 6 by Canaccord Genuity. On Wednesday, June 27 the stock rating was downgraded by SunTrust to “Hold”. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, April 11 report. Oppenheimer maintained Summit Therapeutics plc (NASDAQ:SMMT) rating on Friday, January 26. Oppenheimer has “Outperform” rating and $30 target. SunTrust maintained the shares of SMMT in report on Friday, April 13 with “Buy” rating. The rating was downgraded by Oppenheimer to “Hold” on Wednesday, June 27. See Summit Therapeutics plc (NASDAQ:SMMT) latest ratings:

28/06/2018 Broker: Janney Capital Old Rating: Buy New Rating: Neutral Old Target: $27 New Target: $3 Downgrade
27/06/2018 Broker: Oppenheimer Rating: Hold Downgrade
27/06/2018 Broker: SunTrust Old Rating: Buy New Rating: Hold Old Target: $22 New Target: $4 Downgrade
02/05/2018 Broker: Janney Capital Rating: Buy New Target: $27 Initiates Coverage On
12/04/2018 Broker: Needham Rating: Buy New Target: $27.0000
13/04/2018 Broker: SunTrust Rating: Buy New Target: $22.0000 Maintain
11/04/2018 Broker: Canaccord Genuity Rating: Buy New Target: $28.0000 Maintain
28/03/2018 Broker: JMP Securities Rating: Buy New Target: $42.0000
06/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $28.0 Maintain
13/02/2018 Broker: BTIG Research Rating: Buy New Target: $33 Initiates Coverage On

It closed at $2.38 lastly. It is up 11.61% since June 29, 2017 and is uptrending. It has underperformed by 0.96% the S&P500. Some Historical SMMT News: 03/05/2018 – Summit Therapeutics at Non-Deal Roadshow Hosted By JMP Today; 19/04/2018 – SUMMIT COMPLETES DOSING OF EZUTROMID IN PHASEOUT DMD TRIAL; 27/03/2018 – SUMMIT THERAPEUTICS REPORTS PLACING 8.3M SHRS AT 180 PENCE/SHR; 19/04/2018 – REG-Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial; 13/04/2018 – REG-Summit Therapeutics Files US Annual Report on Form 20F; 19/04/2018 – Summit Therapeutics: Top-line Data On-track to Be Reported During 3rd Quarter; 19/04/2018 – Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial; 28/03/2018 – Summit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual Meeting; 14/03/2018 – SUMMIT HIGHLIGHTS SCIENTIFIC RIGOUR OF ITS PHASEOUT DMD CLINICAL TRIAL AT MDA CLINICAL CONFERENCE; 20/04/2018 – Summit Therapeutics Says Muscular Dystrophy Drug Candidate Appears Effective

More notable recent Summit Therapeutics plc (NASDAQ:SMMT) news were published by: Seekingalpha.com which released: “Summit Therapeutics announces trial failure; shares halted” on June 27, 2018, also Nasdaq.com with their article: “Mid-Afternoon Market Update: US Stocks Turn Negative; Cara Therapeutics Shares Spike Higher” published on June 27, 2018, Schaeffersresearch.com published: “2 Drug Stocks Selling Off on Failed Studies” on June 27, 2018. More interesting news about Summit Therapeutics plc (NASDAQ:SMMT) were released by: Globenewswire.com and their article: “Summit Therapeutics plc : Result of AGM” published on June 07, 2018 as well as Streetinsider.com‘s news article titled: “Summit Therapeutics plc (SMMT) PT Lowered to $5 at BTIG” with publication date: June 27, 2018.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $41.90 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It currently has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

Since May 4, 2018, it had 0 buys, and 1 insider sale for $50,203 activity. The insider McCullough Mark C sold 721 shares worth $50,203.

American Electric Power Company, Inc., a public utility holding company, engages in the generation, transmission, and distribution of electricity for sale to retail and wholesale clients in the United States. The company has market cap of $33.85 billion. The firm generates electricity using coal and lignite, natural gas, nuclear, hydroelectric, solar, wind, and other energy sources. It has a 19.09 P/E ratio. It also supplies and markets electric power at wholesale to other electric utility companies, rural electric cooperatives, municipalities, and other market participants.

Investors sentiment decreased to 0.88 in Q1 2018. Its down 0.20, from 1.08 in 2017Q4. It is negative, as 57 investors sold American Electric Power Company, Inc. shares while 288 reduced holdings. 76 funds opened positions while 229 raised stakes. 347.97 million shares or 0.83% more from 345.12 million shares in 2017Q4 were reported. 154,134 were reported by Suntrust Banks. Aviance Cap Mgmt Limited Co accumulated 16 shares or 0% of the stock. Texas Permanent School Fund has 127,125 shares. Kentucky Retirement Sys holds 0.15% or 25,677 shares in its portfolio. Mitsubishi Ufj & Banking accumulated 1.31M shares. Loomis Sayles & L P holds 0.01% of its portfolio in American Electric Power Company, Inc. (NYSE:AEP) for 65,358 shares. Jpmorgan Chase And Company reported 0.12% in American Electric Power Company, Inc. (NYSE:AEP). Barry Investment Ltd has invested 0.11% in American Electric Power Company, Inc. (NYSE:AEP). Arcadia Inv Management Corp Mi invested in 0.01% or 388 shares. The New York-based Kepos L P has invested 0.2% in American Electric Power Company, Inc. (NYSE:AEP). Clearbridge Invs Limited has 0% invested in American Electric Power Company, Inc. (NYSE:AEP). Duncker Streett accumulated 4,989 shares. Guardian Cap Advsr Limited Partnership invested 0.68% of its portfolio in American Electric Power Company, Inc. (NYSE:AEP). Edgestream Prtn Lp owns 43,055 shares for 0.58% of their portfolio. Berkshire Asset Mgmt Limited Liability Corp Pa has invested 0.2% in American Electric Power Company, Inc. (NYSE:AEP).

American Electric Power Company, Inc. (NYSE:AEP) Institutional Positions Chart